Germany reports decline in cannabis addiction treatment and new limits on medical cannabis coverage
National monitoring data show that after the German Cannabis Act (CanG) legalised adult‑use cannabis in April 2024, outpatient care episodes for cannabis‑use disorder fell by 15% in 2024 compared with 2023. The drop was strongest among people under 25, whose admissions fell by about 24%, and among men, whose cases per facility fell from 23.9 to 19.8, while female admissions remained around 5.5 per facility. Researchers note the decline may reflect fewer referrals from police and courts rather than a true reduction in prevalence.
A separate legislative package enacted on 30 July 2026 removes statutory health‑insurance reimbursement for cannabis flower prescriptions, affecting roughly 65,000 insured patients. Extracts and approved cannabis‑based medicines continue to be reimbursed only after a mandatory six‑month trial of a licensed product. Patient organisations – the Bundesverband Cannabis Wirtschaft, the Bundesverband pharmazeutischer Cannabinoid‑unternehmen, and the Bund Deutscher Cannabis‑Patienten – have lodged legal challenges, arguing the measures place a double burden on seriously ill patients.
Since 1 April 2024 adults are also allowed to cultivate up to three cannabis plants for personal use, with possession limits of 50 g at home and 25 g while travelling. The new framework combines liberalisation of private cultivation with tighter controls on medical‑cannabis financing.
Entities: Bund Deutscher Cannabis-Patienten (BDCan) · Bund Deutscher Cannabis‑Patienten (BDCan) · Bundesverband Cannabis Wirtschaft (BvCW) · Bundesverband pharmazeutischer Cannabinoidunternehmen (BPC) · Frank-Walter Steinmeier · German Cannabis Act · German Cannabis Act (CanG) · German Federal Parliament (Bundestag) · Germany
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [○ 1 SOURCE] Among people under 25, cannabis‑use disorder admissions fell by about 24% in 2024. (Same monitoring study.)
- [● 2 SOURCES] Extracts and approved cannabis pharmaceuticals remain reimbursable only after a mandatory six‑month trial of a licensed product. (GKV‑Spargesetz provisions.)
- [● 2 SOURCES] Male cannabis‑use disorder admissions dropped from 23.9 to 19.8 per facility between 2023 and 2024; female admissions stayed around 5.5 per facility. (Monitoring data.)
- [● 2 SOURCES] Effective 30 July 2026, statutory health‑insurance reimbursement for cannabis flower was removed in Germany, affecting about 65,000 patients. (German GKV‑Spargesetz.)
- [● 2 SOURCES] The German Cannabis Act (CanG) legalised adult‑use cannabis in April 2024. (German law.)
- [● 2 SOURCES] Outpatient care episodes for cannabis‑use disorder declined by 15% in Germany in 2024 compared with 2023. (Study using German Addiction Statistical Service data.)
- [○ 1 SOURCE] Since 1 April 2024, adults in Germany may privately cultivate up to three cannabis plants, with possession limits of 50 g at home and 25 g while travelling. (German Cannabis Act regulations.)
- [○ 1 SOURCE] Patient groups (Bundesverband Cannabis Wirtschaft, Bundesverband pharmazeutischer Cannabinoidunternehmen, Bund Deutscher Cannabis‑Patienten) have filed legal challenges against the insurance cut, deem (Statements from the groups.)